Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody

• US 7,255,860 B2
• Filed: 10/08/2003
• Issued: 08/14/2007
• Est. Priority Date: 10/08/2002
• Status: Active Grant

• Current Assignee: Rinat Neuroscience Corp. (Pfizer Inc.)
• Original Assignee: Rinat Neuroscience Corp. (Pfizer Inc.)
• Inventors: Vergara, German J., Shelton, David L.
• Primary Examiner(s): Saoud; Christine J.
• Assistant Examiner(s): LOCKARD, JON MCCLELLAND
• Application Number:
  US10/682,638
• Publication Number:
  US 20070160605A1
• Time in Patent Office: 1,406 Days
• Field of Search: None
• US Class Current: 424/145.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: C07K 16/22 against growth factors ; against growth regulators
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/52 Constant or Fc region; Isotype

Abstract

The invention features methods and compositions for preventing or treating post-surgical pain by administering an anti-NGF antagonist antibody.

Claims

1. A method for treating post-surgical pain in a human subject comprising administering to the subject in need of such treatment an effective amount of an anti-nerve growth factor (NGF) antagonist antibody, whereby the post-surgical pain in the subject is treated.

2. The method of claim 1, wherein the post-surgical pain comprises resting pain, and wherein the resting pain is ameliorated.

3. The method of claim 1, wherein the post-surgical pain comprises mechanically-induced pain, and wherein the mechanically-induced pain is ameliorated.

4. The method of claim 1, wherein the anti-NGF antagonist antibody is a human antibody.

5. The method of claim 1, wherein the anti-NGF antagonist antibody is a humanized antibody.

6. The method of claim 1, wherein the anti-NGF antagonist antibody binds human NGF.

7. The method of claim 6, wherein the anti-NGF antagonist antibody binds human NGF with a binding affinity of about 0.1 nM or less than about 0.1 nM.

8. The method of claim 1, wherein the post-surgical pain comprises resting pain and mechanically-induced pain, and wherein the resting pain and mechanically-induced pain are ameliorated.

9. The method of claim 1, wherein the post-surgical pain comprises thermally-induced pain, and wherein the thermally-induced pain is ameliorated.

10. The method of claim 1, wherein the post-surgical pain comprises resting pain, mechanically-induced pain, and thermally-induced pain, and wherein the resting pain, mechanically-induced pain, and thermally-induced pain are ameliorated.

11. The method of claim 1, wherein wound healing is not significantly inhibited.